AOD-9604 vs CJC-1295 vs Ipamorelin
A three-way comparison to help you find the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Dose Range | 300 mcg–500 mcg | 1 mg–2 mg | 100 mcg–300 mcg |
| Frequency | 1x daily | Less than daily | 2x daily |
| Cycle Length | 12–24 weeks | 8–12 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous | subcutaneous |
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. |
| Best For |
What They Have in Common
AOD-9604, CJC-1295, Ipamorelin are all commonly used for:
Key Differences
Unique to CJC-1295:
Unique to Ipamorelin:
Which Has Stronger Evidence?
| Goal | AOD-9604 | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Fat Loss | medium | high | high |
Key Studies
AOD-9604
- AOD-9604 does not influence the WADA hGH isoform immunoassay.
Drug testing and analysis, 2013
- AOD-9604 Metabolic.
Current opinion in investigational drugs (London, England : 2000), 2004
CJC-1295
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Drug testing and analysis, 2019
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Drug testing and analysis, 2019
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Substance use & misuse, 2016
Ipamorelin
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
Animal reproduction science, 2024
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Physiology & behavior, 2024
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
International journal of colorectal disease, 2014
Ready to Learn More?
Looking for trusted sources?